Satoko Tanaka1,2, Keisuke Tsumura1, Yukiko Nakura3, Tsugumichi Tokuda4, Hiroaki Nakahashi2, Tomoko Yamamoto2, Takeshi Ono1, Itaru Yanagihara3, Makoto Nomiyama1. 1. Department of Obstetrics and Gynecology, National Hospital Organization, Saga Hospital, Saga, Japan. 2. Department of Obstetrics and Gynecology, Faculty of Medicine, Saga University, Saga, Japan. 3. Department of Developmental Medicine, Research Institute, Osaka Medical Center for Maternal and Child Health, Osaka, Japan. 4. Department of Obstetrics and Gynecology, National Hospital Organization, Kokura Medical Center, Kokura, Japan.
Abstract
AIM: The optimal antibiotic regimen for preterm premature rupture of membrane (pPROM) is still unclear. This study aimed to determine the effects of ampicillin-sulbactam (SBT/ABPC) and azithromycin (AZM) on the incidence of bronchopulmonary dysplasia (BPD). METHODS: This retrospective study included women with singleton gestations and a diagnosis of pPROM between 22 and 27 weeks of gestation. In patients presenting with a high risk of intra-amniotic infection between January 2011 and May 2013, piperacillin or cefmetazole + clindamycin (regimen 1 group; n = 11) was administered, whereas SBT/ABPC and AZM (regimen 2 group; n = 11) were administered in patients presenting a similar risk between June 2013 and May 2016. RESULTS: The incidence of moderate or severe infant BPD in the regimen 2 group was significantly lower than that in the regimen 1 group, even when adjusted for gestational age at the time of rupture of membrane, with an odds ratio (95% confidence interval) of 0.02 (1.8 × 10-5 -0.33). The incidence of BPD and total days on mechanical ventilation were significantly lower in the regimen 2 group than in the regimen 1 group. No significant differences were seen in other morbidities. CONCLUSION: In patients with pPROM between 22 and 27 weeks of gestation, the administration of SBT/ABPC and AZM may improve the perinatal outcomes.
AIM: The optimal antibiotic regimen for preterm premature rupture of membrane (pPROM) is still unclear. This study aimed to determine the effects of ampicillin-sulbactam (SBT/ABPC) and azithromycin (AZM) on the incidence of bronchopulmonary dysplasia (BPD). METHODS: This retrospective study included women with singleton gestations and a diagnosis of pPROM between 22 and 27 weeks of gestation. In patients presenting with a high risk of intra-amniotic infection between January 2011 and May 2013, piperacillin or cefmetazole + clindamycin (regimen 1 group; n = 11) was administered, whereas SBT/ABPC and AZM (regimen 2 group; n = 11) were administered in patients presenting a similar risk between June 2013 and May 2016. RESULTS: The incidence of moderate or severe infant BPD in the regimen 2 group was significantly lower than that in the regimen 1 group, even when adjusted for gestational age at the time of rupture of membrane, with an odds ratio (95% confidence interval) of 0.02 (1.8 × 10-5 -0.33). The incidence of BPD and total days on mechanical ventilation were significantly lower in the regimen 2 group than in the regimen 1 group. No significant differences were seen in other morbidities. CONCLUSION: In patients with pPROM between 22 and 27 weeks of gestation, the administration of SBT/ABPC and AZM may improve the perinatal outcomes.
Authors: Marian Kacerovsky; Roberto Romero; Martin Stepan; Jaroslav Stranik; Jan Maly; Lenka Pliskova; Radka Bolehovska; Vladimir Palicka; Helena Zemlickova; Helena Hornychova; Jiri Spacek; Bo Jacobsson; Percy Pacora; Ivana Musilova Journal: Am J Obstet Gynecol Date: 2020-07 Impact factor: 10.693
Authors: Ping Luo; Kun Zhang; You Chen; Xiuwen Geng; Tong Wu; Li Li; Ping Zhou; Ping-Ping Jiang; Liya Ma Journal: Front Pediatr Date: 2021-12-22 Impact factor: 3.418
Authors: Nathalia M Noda-Nicolau; Ourlad Alzeus G Tantengco; Jossimara Polettini; Mariana C Silva; Giovana F C Bento; Geovanna C Cursino; Camila Marconi; Ronald F Lamont; Brandie D Taylor; Márcia G Silva; Daniel Jupiter; Ramkumar Menon Journal: Front Microbiol Date: 2022-03-30 Impact factor: 5.640